There is one clinical trial.
The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring hospitalization. The hypothesis of the Study is autologous adipose-derived mesenchymal cells given IV to eligible patients will improve clinical outcomes of COVID 19 positive patients with severe pneumonia or ARDS by reducing or avoiding cytokine storm.
Description: Incidence of unexpected adverse events within 28 days following IV administration of MSCs.Measure: Safety - Incidence of unexpected adverse events Time: up to 28 days
Description: Changes in progression or rate of subjects progressing to mechanical ventilationMeasure: Efficacy - Frequency of progression to mechanical ventilation Time: up to 28 days
Description: Changes in time subjects remain on mechanical ventilationMeasure: Efficacy - Changes in length of mechanical ventilation Time: up to 28 days
Description: Changes in length of time subjects wean off of mechanical ventilationMeasure: Efficacy - Changes in length of weaning of mechanical ventilation Time: up to 28 days
Description: Length of Hospital StayMeasure: Efficacy - Changes in length of hospital stay Time: up to 28 days
Description: Mortality rate from all causesMeasure: Efficacy - Changes in mortality rate Time: up to 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports